Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price

Executive Summary

Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.

You may also be interested in...



Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives

Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.

Part D Point-Of-Sale Rebates Losing Appeal? CBO Confirms Big Cost To Medicare

Congressional Budget Office agrees with the Office of Management and Budget that passing through negotiated rebates to Medicare Part D beneficiaries at the point-of-sale would significantly increase Medicare spending.

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

The reform 'blueprint' might actually live up to its hype.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

SC123424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel